



Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Benjamin Lebwohl, M.D., M.S.**

Committee: **Gastrointestinal Drugs Advisory Committee (GIDAC)**

Meeting Date: **October 18, 2018**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: new drug application (NDA) 210166, for prucalopride tablets for oral administration, submitted by Shire Development, LLC, proposed for the treatment of chronic idiopathic constipation (CIC) in adults, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Stocks/investments	(b) (6) a healthcare sector mutual fund	Between \$200,000-\$300,000
<b>II. Other Imputed Interests</b>		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of this interest, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/  
Signature

\_\_\_\_\_  
9/22/2018  
Date